← All trials
NCT06897644
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 27, 2025
- Primary completion
- Jan 1, 2029
- Completion date
- Jan 1, 2030
- First posted
- Mar 27, 2025
- Last posted
- May 25, 2025
- Enrollment
- 340
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Gruppo Oncologico del Nord-OvestLead sponsor
- Rising Tide FoundationCollaborator
- University of MilanOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.